

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
14 December 2000 (14.12.2000)

PCT

(10) International Publication Number  
**WO 00/75107 A2**(51) International Patent Classification<sup>7</sup>: C07C 311/44,  
C07D 211/62, 211/34, 401/12, 295/18, A61K 31/63, A61P  
29/00BA2 4RU (GB). HART, Terance, William [GB/GB]; 12  
Perry Court, Clerk Maxwell Road, Cambridge CB3 0RS  
(GB). RITCHIE, Timothy, John [GB/GB]; 56 Burrard  
Road, London NW6 1DD (GB). WAYKOLE, Liladhar  
[US/US]; 11 Putters Road, Succasunna, NJ 07876 (US).

(21) International Application Number: PCT/EP00/05059

(22) International Filing Date: 2 June 2000 (02.06.2000)

(74) Agent: BECKER, Konrad; Novartis AG, Corporate In-  
tellectual Property, Patent & Trademark Dept., CH-4002  
Basel (CH).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9913079.1 4 June 1999 (04.06.1999) GB(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,  
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,  
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,  
TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(71) Applicant (*for all designated States except AT, US*): NO-  
VARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058  
Basel (CH).(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).(71) Applicant (*for AT only*): NOVARTIS-ERFINDUNGEN  
VERWALTUNGSGESELLSCHAFT MBH [AT/AT];  
Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BRAIN, Christo-  
pher, Thomas [GB/GB]; 54 Cardinal's Gate, Wer-  
rington, Peterborough, Cambridgeshire PE7 5A (GB).  
CANTRELL, William [US/US]; 307 Laurel Ridge Drive,  
San Antonio, TX 78253 (US). CULSHAW, Andrew,  
James [GB/GB]; 10 Bracewell Avenue, Greenford, Mid-  
dlesex UB6 7QU (GB). DZIADULEWICZ, Edward,  
Karol [GB/GB]; 83 Wellsway, Bear Flat, Bath, Somerset

## Published:

— Without international search report and to be republished  
upon receipt of that report.For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: BRADYKININ RECEPTOR ANTAGONISTS


(57) Abstract: Novel sulfonyl amine derivatives, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.

WO 00/75107 A2

Bradykinin receptor antagonists

The present invention relates to novel sulfonyl amine derivatives, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

More particularly the present invention provides in a first aspect, a compound of formula IA



wherein

$\text{R}^{5A}$  is  $-\text{X}^A-\text{R}^{6A}$  or  $-\text{N}(\text{R}^{7A})\text{R}^{8A}$ , wherein

$\text{X}^A$  is piperidinylene or piperazinylene,

$\text{R}^{6A}$  is H,  $\text{C}_1$ - $\text{C}_4$ alkyl,  $\text{C}_3$ - $\text{C}_4$ alkenyl,  $\text{C}_3$ - $\text{C}_4$ alkinyl,  $\text{C}_1$ - $\text{C}_4$ (alkoxyalkyl),  $\text{C}_1$ - $\text{C}_4$ (carboxyalkyl), a  $\text{C}_5$ - $\text{C}_7$ heterocyclic group or phenyl- $\text{C}_1$ - $\text{C}_4$ alkyl;

$\text{R}^{7A}$  is amino- $\text{C}_2$ - $\text{C}_4$ alkyl or mono- or di- $(\text{C}_1$ - $\text{C}_5$ alkyl)amino- $\text{C}_2$ - $\text{C}_5$ alkyl, and

$\text{R}^{8A}$  is H,  $\text{C}_1$ - $\text{C}_4$ alkyl or has the meanings as given for  $\text{R}^{7A}$ ;

$\text{X}^1$  is a divalent group of formula IA'  $-(\text{CH}_2)_n-\text{X}^3(\text{CH}_2)_m-\text{X}^4-\text{N}(\text{R}^{3A})$  wherein

$n$  is zero or 1;

$\text{X}^3$  is CH or N;

(a)  $\text{X}^4$  is a direct bond,  $\text{R}^{3A}$  and  $\text{R}^{4A}$  together are ethylene and  $m$  is 2; or

(b)  $\text{X}^4$  is a direct bond,  $\text{R}^{3A}$  is H,  $\text{C}_1$ - $\text{C}_4$ alkyl,  $\text{C}_3$ - $\text{C}_6$ cycloalkyl,  $\text{C}_3$ - $\text{C}_6$ alkenyl,  $\text{C}_3$ - $\text{C}_6$ alkinyl,  $\text{C}_7$ - $\text{C}_{10}$ aralkyl or  $\text{C}_6$ - $\text{C}_9$ heteroaralkyl,  $\text{R}^{4A}$  is H and  $m$  is 1 or 2 or 3; or

(c)  $\text{X}^4$  is  $-\text{CH}(\text{R}^{12})-$ ,  $\text{R}^{3A}$  is H and  $\text{R}^{4A}$  and  $\text{R}^{12}$  together are propylene and  $m$  is 1, or ethylene and  $m$  is 2;



$\text{X}^3$  is CH or N; and

$\text{R}^{11}$  is  $\text{C}_1$ - $\text{C}_4$ alkyl,  $\text{C}_3$ - $\text{C}_6$ cycloalkyl or  $-\text{NR}^{1A}\text{R}^{2A}$ , wherein


$\text{R}^{1A}$  and  $\text{R}^{2A}$  independently are  $\text{C}_1$ - $\text{C}_4$ alkyl or, together with the N-atom to which they are attached, represent a 5 to 7 membered heterocyclic ring; and

$R^9$  and  $R^{10}$  independently are a phenyl or pyridine ring;  
and salts thereof.

It will be understood that the above defined compounds may bear substituents within their structure, e.g. may bear appropriate phenyl ring or alkylene moiety substituents, e.g. phenyl and pyridine in the meaning of  $R^9$  or  $R^{10}$  may be unsubstituted or substituted by one or more halogen, and in the meaning of  $R^{3A}$  alkyl may be unsubstituted or substituted by halogen,  $C_3$ - $C_6$ cycloalkyl or aryl; aralkyl may be unsubstituted or substituted by halogen, methoxy, nitro or  $C_1$ - $C_4$ alkyl which may be unsubstituted or substituted by halogen; heteroaralkyl may be unsubstituted or substituted by  $C_1$ - $C_4$ alkyl. The amino moiety of the defined aminocarbonyl or amide groupings can be any appropriate amino grouping, e.g. cyclic or aliphatic or may bear further substituent groupings.

Even more particularly the present invention provides a 2-(2,2-diphenylethylamino)-5-(4-aminocarbonyl-piperidine-1-sulfonyl)-benzoic acid amide or -5-(aminocarbonyl- $C_2$ - $C_4$ alkyleneaminosulfonyl)-benzoic acid amide, or salt thereof.

Preferred compounds in accordance with the invention are those of formula I



wherein


$R^1$  and  $R^2$  independently are  $C_1$ - $C_4$ alkyl or, together with the N-atom to which they are attached, represent a 5 to 7 membered heterocyclic ring;

(a)  $R^3$  and  $R^4$  together are ethylene and m is 2; or

(b)  $R^3$  is H,  $C_1$ - $C_4$ alkyl,  $C_5$ - $C_7$ cycloalkyl or phenyl- $C_1$ - $C_4$ alkyl,  $R^4$  is H and m is 1 or 2 or 3;

n is zero or 1; and

$R^5$  is  $-X-R^6$  or  $-N(R^7)R^8$ , wherein



$R^6$  is  $C_1$ - $C_4$ alkyl,  $C_3$ - $C_4$ alkenyl,  $C_3$ - $C_4$ alkinyl,  $C_1$ - $C_4$ (alkoxyalkyl),  $C_1$ - $C_4$ (carboxyalkyl), a  $C_5$ - $C_7$ heterocyclic group or phenyl- $C_1$ - $C_4$ alkyl;

$R^7$  is amino- $C_2$ - $C_4$ alkyl or mono- or di- $(C_1$ - $C_5$ alkyl)amino- $C_2$ - $C_5$ alkyl, and

$R^8$  is H,  $C_1$ - $C_4$ alkyl or has the meanings as given for  $R^7$ ;

and salts thereof.

Alkyl groups and moieties in the compounds of formula IA or I may be branched or straight chain. Alkyl groups are suitably straight chain.

Heterocyclic groups may be saturated or unsaturated and may contain one or more additional heterocyclic atoms, e.g. oxygen or sulfur. Examples include piperidin-1-yl, morpholin-1-yl, 3,6-dihydro-2H-pyridin-1-yl, thiomorpholin-1-yl, pyrrolin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, 3,6-dihydro-2H-pyridin-1-yl, 2,5-dihydropyrrol-1-yl and 4-difluoropiperidin-1-yl, and may be unsubstituted or substituted by one or two halogen atoms.

Compounds of the invention exist in free or salt, e.g. acid addition salt form. The invention is to be understood as including both the compounds of formula IA or I in free as well as in salt form, e.g. as trifluoroacetate or hydrochloride salt. Suitable pharmaceutically acceptable acid addition salts for pharmaceutical use in accordance with the invention include in particular the hydrochloride salt.

In formula IA the following significances are preferred independently, collectively or in any combination or sub-combination:

(a')  $R^{5A}$  is unsubstituted piperazinyl or piperazinyl substituted by methyl, ethyl, benzyl, 2-pyridinyl, methoxyethyl, carboxymethyl or  $-CH_2CHCH_2$ ; or piperidine substituted by methyl;

(a'')  $R^{5A}$  is  $N(R^{7A})R^{8A}$  wherein  $R^{7A}$  is aminopropyl, aminobutyl, dimethylaminopropyl, diethylaminopropyl, dibutylaminoethyl, dimethylaminobutyl, or dimethylaminopentyl; and  $R^{8A}$  is H, methyl, aminopropyl, aminobutyl, dimethylaminopropyl or dimethylaminobutyl;


(b')  $X^1$  is  $-(CH_2)_n-CH(R^{4A})-(CH_2)_2-N(R^{3A})-$  wherein n is zero or 1 and  $R^{3A}$  and  $R^{4A}$  together are ethylene;

- (b'')  $X^1$  is  $-\text{CH}(\text{R}^{4A})-(\text{CH}_2)_m-\text{CH}(\text{R}^{12})-\text{NH}-$  wherein  $m$  is 1 or 2 and  $\text{R}^{4A}$  and  $\text{R}^{12}$  together are propylene or ethylene;
- (b''')  $X^1$  is  $-(\text{CH}_2)_n-\text{CH}_2-(\text{CH}_2)_m-\text{N}(\text{R}^{3A})-$  wherein  $n$  is zero or 1,  $m$  is 1 or 2 or 3 and  $\text{R}^{3A}$  is H, methyl, isopropyl, isobutyl, fluoroethyl, cyclopropylmethyl, cyclohexylmethyl, cyclobutylmethyl,  $-\text{CH}(\text{CH}_3)\text{C}_6\text{H}_5$ , cyclohexyl, propenyl, butenyl, pentenyl, propinyl, butinyl, pentinyl, benzyl, methylbenzyl, fluorobenzyl, trifluoromethylbenzyl, methoxybenzyl, nitrobenzyl, pyridinylmethyl, methylisoxazolylmethyl, methylthiazolylmethyl or thiophenemethyl;
- (c')  $X^2$  is a divalent group of formula  $\text{IA}''$  wherein  $X^3$  is CH and  $\text{R}^{11}$  is methyl, cyclopentyl, cyclohexyl,  $\text{N}(\text{CH}_3)\text{CH}_2\text{CH}_3$ , piperidiny, morpholinyl, thiomorpholinyl, dihydropyridinyl, dihydropyrrolyl or difluoropiperidiny;
- (c'')  $X^2$  is a divalent group of formula  $\text{IA}''$  wherein  $X^3$  is N and  $\text{R}^{11}$  is morpholinyl;
- (d)  $\text{R}^9$  and  $\text{R}^{10}$  are phenyl which is unsubstituted or substituted by halogen;
- (d'')  $\text{R}^9$  is phenyl and  $\text{R}^{10}$  is pyridine.

In formula I the following significances are preferred independently, collectively or in any combination or sub-combination:

- (a<sup>1</sup>)  $\text{R}^1$  and  $\text{R}^2$  are independently methyl or ethyl.
- (a<sup>2</sup>)  $\text{R}^1$  and  $\text{R}^2$  together with the N-atom to which they are attached are piperidin-1-yl, morpholin-1-yl, 3,6-dihydro-2.H.pyridin-1-yl, thiomorpholin-1-yl or pyrrolin-1-yl.
- (b<sup>1</sup>)  $\text{R}^3$  and  $\text{R}^4$  together are ethylene and  $m$  is 2.
- (b<sup>2</sup>)  $\text{R}^3$  is H, methyl, cyclohexyl or benzyl;  $\text{R}^4$  is H and  $m$  is 1 or 2 or 3, especially 1.
- (c)  $n$  is zero or 1.
- (d<sup>1</sup>)  $\text{R}^5$  is  $-\text{X}-\text{R}^6$ , wherein  $\text{R}^6$  is  $\text{C}_1$ - $\text{C}_4$ alkyl (e.g. methyl, ethyl or isopropyl), 3-propenyl, methoxyethyl, carboxymethyl, 2-pyridyl, or benzyl, and  $\text{X}$  is as defined above.
- (d<sup>2</sup>)  $\text{R}^5$  is  $-\text{N}(\text{R}^7)\text{R}^8$ , wherein  $\text{R}^7$  is aminopropyl, aminobutyl, dipropylaminoethyl, dimethylaminopropyl, dimethylaminobutyl, diethylaminopropyl or dimethylaminopentyl; and  $\text{R}^8$  is H, methyl, aminopropyl, aminobutyl, dimethylaminopropyl or dimethylaminobutyl.

In addition to the foregoing the present invention also provides a process for the production of a compound of formula IA which process comprises reacting a compound of formula IIA




wherein  $\text{X}^1$ ,  $\text{X}^2$ ,  $\text{R}^9$  and  $\text{R}^{10}$  have the meanings given for formula IA,  
with an amine, e.g. of formula IIIA



wherein  $\text{R}^{5A}$  has the meanings given for formula IA,  
and recovering the obtained compound, e.g. of formula IA, in free or in salt form, e.g. acid addition salt form.

The present invention also provides a process for the production of a 2-(2,2-diphenylethyl-amino)- 5-(4-aminocarbonyl-piperidine-1-sulfonyl)-benzoic acid amide or 5-(aminocarbonyl- $\text{C}_{2-4}$ alkylene aminosulfonyl)-benzoic acid amide, for example a compound of formula I as defined above, or salt thereof, which process comprises reacting a 2-(2,2-diphenylethylamino)- 5-(4-carboxy-piperidine-1-sulfonyl)-benzoic acid amide or 5-(carboxy- $\text{C}_{2-4}$ alkylene aminosulfonyl)-benzoic acid amide, for example a compound of formula II



wherein  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $m$  and  $n$  have the meanings given for formula I,  
with an amine, e.g. of formula III



wherein  $\text{R}^5$  has the meanings given for formula I,  
and recovering the obtained compound, e.g. of formula I, in free or in salt form, e.g. acid addition salt form.

The reaction may be carried out in accordance with standard procedures, for example by a first acid chloride formation step using e.g. thionyl chloride and catalytic DMF in an inert solvent, e.g.  $\text{CH}_2\text{Cl}_2$ , at ambient temperature, followed by the coupling step involving addition of the acid chloride to a mixture of the amine and e.g. TEA, at a temperature of, e.g.  $-10^\circ\text{C}$ . Aqueous

workup followed by precipitation from, e.g. ethyl acetate gives the free base. The salt forms are made by standard procedures known to the skilled artisan.

In the examples the following abbreviations are used: DMF: dimethyl formamide; DMSO: dimethyl sulfoxide; EDTA: ethylenediamine-tetraacetic acid; EtOAc: ethylacetate; IPA: isopropanol; RT: room temperature; TBME: t-butyl methyl ether; TBTU: (O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; TEA: triethylamine; TFA: trifluoroacetic acid; THF: tetrahydrofuran.

**Example 1: Preparation of {2-(2,2-diphenyl-ethylamino)-5-[4-(4-isopropyl-piperazine-1-carbonyl)-piperidine-1-sulfonyl]-phenyl}-morpholin-4-yl-methanone**  
(formula I:  $R^1 + R^2 + N = \text{morpholin-4-yl}$ ,  $R^3 + R^4 = \text{ethylene}$ ,  $m = 2$ ,  $n = \text{zero}$ ,  $R^5 = 4\text{-isopropyl-piperazin-1-yl}$ )

(a) A 5 liter flask is charged with {2-(2,2-diphenyl-ethylamino)-5-[4-(4-carboxy)-piperidine-1-sulfonyl]-phenyl}-morpholin-4-yl-methanone (130.2 g),  $\text{CH}_2\text{Cl}_2$  (1.3 l), DMF (0.82 g) and thionyl chloride (18.1 ml, 29.51 g). The suspension is stirred at ambient temperature (the solids dissolved after ~2 h). The volatiles are removed by rotary evaporation (30°C, house vacuum) and the crude acid chloride is redissolved in  $\text{CH}_2\text{Cl}_2$  (300 ml). The solution of acid chloride is added to a mixture of isopropylpiperazine (47.60 g), TEA (98.09 g) and  $\text{CH}_2\text{Cl}_2$  (1 l) at -10°C over 1 h. The reaction is worked up by removing volatiles via rotary evaporation. The residue is suspended in EtOAc (2.0 l) and washed with water (2 x 500 ml), brine (500 ml) and dried ( $\text{Na}_2\text{SO}_4$ ). The volume is reduced by rotary evaporation (35°C, house vacuum) to ~500 ml and stirred at ambient temperature for 17 h. The suspension is filtered and dried (40°C, house vacuum) to give the title compound as free base.

(b) A 5 liter flask is charged with the above compound (121.3 g),  $\text{CH}_2\text{Cl}_2$  (1.2 l), and 37 % HCl (17.38 g). After stirring for 30 min, the volatiles are removed by rotary evaporation and the residue is triturated with IPA (1 l). The suspension is filtered and dried (40°C, house vacuum) to give the crude HCl salt of the title compound.

(c) A 2 liter flask is charged with the above crude HCl salt (133.7 g), silica gel (13.0 g) and  $\text{CH}_2\text{Cl}_2$  (1.3 l). The mixture is stirred for 15 min at ambient temperature and then filtered. This process is repeated twice more. The solvent is removed by rotary evaporation. The residue is suspended in a mixture of IPA (1.0 l) and water (100 ml) and heated to reflux. The solution is allowed to cool to ambient temperature and stir for 17 h. The resulting sus-

pension is filtered and dried. The solid is suspended in acetone (1.0 l) and refluxed for 4.5 h. The suspension is cooled to ambient temperature and stirred for 3 days. The suspension is filtered and dried (60°C, house vacuum, 2 days) to give the title compound as HCl salt.

In the following examples compounds of formula IA wherein  $R^{3A}$  and  $R^{4A}$  together are ethylene, m is 2,  $X^3$  is CH and  $R^{5A}$  is  $-X^A-R^{6A}$  wherein  $X^A$  is piperazin-1,4-ylene, are prepared analogously to Example 1:

Example	$R^{11}$	n	$R^{6A}$	$R^9/R^{10}$
2*	morpholin-4-yl	0	-CH <sub>3</sub>	phenyl
3*	3,6-dihydro-2H-pyridin-1-yl	0	-CH <sub>3</sub>	phenyl
4	piperidin-1-yl	0	-CH <sub>3</sub>	phenyl
5*	morpholin-4-yl	0	-CH <sub>2</sub> CH <sub>3</sub>	phenyl
6	thiomorpholin-4-yl	0	-CH <sub>3</sub>	phenyl
7*	morpholin-4-yl	0	benzyl	phenyl
8	-N(CH <sub>3</sub> )CH <sub>2</sub> CH <sub>3</sub>	0	-CH <sub>3</sub>	phenyl
9*	morpholin-4-yl	0	-CH <sub>2</sub> CHCH <sub>2</sub>	phenyl
10*	morpholin-4-yl	0	-CH <sub>2</sub> CH <sub>2</sub> OCH <sub>3</sub>	phenyl
11*	3,6-dihydro-2H-pyridin-1-yl	0	-CH(CH <sub>3</sub> )CH <sub>3</sub>	phenyl
12*	morpholin-4-yl	0	2-pyridinyl	phenyl
13	2,5-dihydropyrrol-1-yl	0	-CH <sub>3</sub>	phenyl
14	3,6-dihydro-2H-pyridin-1-yl	1	-CH <sub>3</sub>	phenyl
15	morpholin-4-yl	0	-CH <sub>2</sub> C(O)OH	phenyl
1.1	morpholin-4-yl	1	-CH <sub>3</sub>	phenyl
1.2	-CH <sub>3</sub>	0	-CH <sub>3</sub>	phenyl
1.3	morpholin-4-yl	0	-CH <sub>3</sub>	4-Cl-phenyl
1.4	-C <sub>5</sub> H <sub>9</sub>	0	-CH <sub>3</sub>	phenyl
1.5	-C <sub>6</sub> H <sub>11</sub>	0	-CH <sub>3</sub>	phenyl
1.6	morpholin-4-yl	0	-CH <sub>3</sub>	4-F-phenyl
1.7	4-difluoropiperidin-1-yl	0	-CH <sub>3</sub>	phenyl
1.8	morpholin-4-yl	0	-H	phenyl

\* as trifluoroacetate



In the following examples compounds of formula I wherein  $R^3$  and  $R^4$  together are ethylene, m is 2 and  $R^5$  is  $-N(R^7)R^8$  are prepared analogously to Example 1:

Example	$-NR^1R^2$	n	$R^7$	$R^8$
16	3,6-dihydro-2H-pyridin-1-yl	0	$-(CH_2)_3N(CH_3)_2$	$-(CH_2)_3N(CH_3)_2$
17	morpholin-4-yl	0	$-(CH_2)_4NH_2$	$-(CH_2)_3NH_2$
18	morpholin-4-yl	0	$-(CH_2)_3N(CH_3)_2$	$-(CH_2)_4N(CH_3)_2$
19	morpholin-4-yl	0	$-(CH_2)_3N(CH_3)_2$	$-CH_3$
20	morpholin-4-yl	0	$-(CH_2)_3N(CH_2CH_3)_2$	$-H$
21	morpholin-4-yl	0	$-(CH_2)_2N[(CH_2CH(CH_3)_2)_2]$	$-H$
22	morpholin-4-yl	0	$-CH_2C(CH_3)_2CH_2N(CH_3)_2$	$-H$

In the following examples compounds of formula IA wherein n is 0, m is 2,  $X^4$  is a direct bond,  $R^{3A}$  and  $R^{4A}$  together are ethylene and  $R^{11}$  is morpholin-4-yl are prepared analogously to Example 1:

Example	$R^{5A}$	$X^3$	$X^5$	$R^9$	$R^{10}$
3.1	4-methylpiperazin-1-yl	N	C	phenyl	phenyl
3.2	4-methylpiperazin-1-yl	C	N	phenyl	phenyl
3.3	1-methyl-piperidin-4-yl	N	C	phenyl	phenyl
3.4	4-methylpiperazin-1-yl	C	C	phenyl	pyridine

In the following examples compounds of formula IA wherein  $R^{3A}$  is H,  $R^{5A}$  is 4-methylpiperazin-1-yl,  $R^9$  and  $R^{10}$  are phenyl,  $R^{11}$  is morpholin-4-yl, n is 0,  $X^3$  and  $X^5$  are CH and  $X^4$  is  $-CH(R^{12})-$  are prepared analogously to Example 1:

Example	$R^{4A} + R^{12}$ together	m
4.1	propylene	1
4.2	ethylene	2

In the following examples compounds of formula IA wherein  $R^{1A}$  and  $R^{2A}$  together with the N-atom to which they are attached are morpholin-4-yl,  $R^{4A}$  is H and  $R^{5A}$  is  $-X^A-R^{6A}$  wherein  $X^A$  is piperazin-1,4-ylene, are prepared analogously to Example 1:

Example	R <sup>3A</sup>	m	n	R <sup>6A</sup>
23	-CH <sub>3</sub>	1	1	-CH <sub>3</sub>
24*	-CH <sub>3</sub>	1	1	-CH(CH <sub>3</sub> )CH <sub>3</sub>
25*	benzyl	1	0	-CH <sub>3</sub>
26*	cyclohexyl	1	0	-CH <sub>3</sub>
27*	-CH <sub>3</sub>	1	0	-CH(CH <sub>3</sub> )CH <sub>3</sub>
28*	benzyl	1	1	-CH(CH <sub>3</sub> )CH <sub>3</sub>
29	-H	2	1	-CH(CH <sub>3</sub> )CH <sub>3</sub>
30	-CH <sub>3</sub>	3	1	-CH <sub>3</sub>
5.1	-CH <sub>2</sub> C <sub>3</sub> H <sub>5</sub>	2	0	-CH <sub>3</sub>
5.2	2-methylbenzyl	2	0	-CH <sub>3</sub>
5.3	2-fluorobenzyl	2	0	-CH <sub>3</sub>
5.4	3-methylbenzyl	2	0	-CH <sub>3</sub>
5.5	3-fluorobenzyl	2	0	-CH <sub>3</sub>
5.6	4-methylbenzyl	2	0	-CH <sub>3</sub>
5.7	4-fluorobenzyl	2	0	-CH <sub>3</sub>
5.8	-CH <sub>2</sub> CH <sub>2</sub> F	2	0	-CH <sub>3</sub>
5.9	-CH(CH <sub>3</sub> )C <sub>6</sub> H <sub>5</sub>	2	0	-CH <sub>3</sub>
5.10	-CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>	2	0	-CH <sub>3</sub>
5.11	-CH <sub>2</sub> C(CH <sub>2</sub> )CH <sub>3</sub>	2	0	-CH <sub>3</sub>
5.12	2-trifluoromethylbenzyl	2	0	-CH <sub>3</sub>
5.13	3-trifluoromethylbenzyl	2	0	-CH <sub>3</sub>
5.14	4-trifluoromethylbenzyl	2	0	-CH <sub>3</sub>
5.15	3-methoxybenzyl	2	0	-CH <sub>3</sub>
5.16	4-methoxybenzyl	2	0	-CH <sub>3</sub>
5.17	2-nitrobenzyl	2	0	-CH <sub>3</sub>
5.18	3-nitrobenzyl	2	0	-CH <sub>3</sub>
5.19	pyridin-3-ylmethyl	2	0	-CH <sub>3</sub>
5.20	pyridin-4-ylmethyl	2	0	-CH <sub>3</sub>
5.21	-CH <sub>2</sub> CHCH <sub>2</sub>	2	0	-CH <sub>3</sub>
5.22	-CH <sub>2</sub> CCH	2	0	-CH <sub>3</sub>

Compound	R <sup>3A</sup>	m	n	R <sup>6A</sup>
5.23	5-methylisoxazol-3-ylmethyl	2	0	-CH <sub>3</sub>
5.24	2-methylthiazol-4-ylmethyl	2	0	-CH <sub>3</sub>
5.25	-CH <sub>2</sub> CHC(CH <sub>3</sub> ) <sub>2</sub>	2	0	-CH <sub>3</sub>
5.26	-CH <sub>2</sub> CHCHCH <sub>3</sub>	2	0	-CH <sub>3</sub>
5.27	-CH <sub>2</sub> C <sub>6</sub> H <sub>11</sub>	2	0	-CH <sub>3</sub>
5.28	-CH <sub>2</sub> C <sub>4</sub> H <sub>7</sub>	2	0	-CH <sub>3</sub>
5.29	-CH <sub>2</sub> CCCH <sub>3</sub>	2	0	-CH <sub>3</sub>
5.30	thiophen-3-ylmethyl	2	0	-CH <sub>3</sub>
5.31	thiophen-2-ylmethyl	2	0	-CH <sub>3</sub>
5.32	-CH <sub>2</sub> CCCH <sub>2</sub> CH <sub>3</sub>	2	0	-CH <sub>3</sub>
5.33	-CH(CH <sub>3</sub> ) <sub>2</sub>	2	0	-CH <sub>3</sub>

### CHARACTERISING DATA

Compounds of the above tables are found to exhibit the following HPLC retention data [min]:


[min]	[min]	[min]	[min]
5.91*	7.17****	24.95***	6.083*
5.68*	5.0*****	5.90*	6.100*
6.22*	5.7*****	6.23*	6.067*
5.43**	24.03***	5.35*	5.967*
23.55***	4.6****	5.75*	4.767*
5.24**	20.1***	5.833*	4.667*
25.93***	22.6***	6.367*	5.567*
5.09**	22.58***	6.100*	6.02*
23.98***	27.57***	6.250*	6.138*
23.89***	22.9***	6.167*	6.087*
6.37*	5.03*****	6.45*	6.558*
23.68***	5.8*	6.200*	6.382*
5.10**	5.83*	5.467	6.932*
6.17****	3.4*****	6.167*	6.547*
5.28****	5.467*	5.900*	6.26*
4.95*****	5.822*	6.338*	6.453*

Peak	[min]	Peak	[min]	Peak	[min]	Peak	[min]
1	6.00****	2	5.57*	3	6.998*	4	5.7*****
5	6.4****	6	5.9*	7	6.983*	8	5.7*****
9	6.82****	10	23.82***	11	7.03*	12	6.510*


HPLC conditions:

- \*: Hypersil 3 micron C 18 BDS column. Gradient elution 10-100% MeCN in water (+0.1% TFA) over 10 min
- \*\* : Kingsorb 50x4.6mm C18 column, 3micron particle size; flow rate 3ml/min; 90% water (+10mM NH<sub>4</sub>OAc 0.3% HCOOH) 10% MeCN to 100% MeCN over 10min
- \*\*\*: Nucleosil 5 micron C18 column, 25cm x 4.6mm. Gradient elution 10-100% MeCN in water (+0.1% TFA) over 40 min
- \*\*\*\*: Waters Symmetry 3 micron C18 column; 5 x 0.46 cm. Gradient elution, 10% to 100% MeCN in water (+ 0.1% TFA) over 10 min
- \*\*\*\*\*: Kingsorb 3 micron C18 column, 30x4.6mm, gradient elution 10 % MeCN in water (+0.1% TFA) to 100% MeCN over 10 min

Compounds of formula IIA wherein X<sup>1</sup>, R<sup>9</sup> and R<sup>10</sup> have the above meanings and X<sup>2</sup> is a divalent group of formula




wherein R<sup>1A</sup> and R<sup>2A</sup> independently are C<sub>1</sub>-C<sub>4</sub>alkyl or, together with the N-atom to which they are attached, represent a 5 to 7 membered heterocyclic ring, may be prepared applying known techniques, e.g. in accordance with the following reaction scheme:




wherein Hal is halogen, e.g. chlorine, R<sup>15</sup> is C<sub>1</sub>-C<sub>4</sub>alkyl, e.g. ethyl, and X<sup>1</sup>, X<sup>2</sup>, R<sup>1A</sup>, R<sup>2A</sup>, R<sup>9</sup> and R<sup>10</sup> are as defined for formula IA.

Each of the above reaction steps may be carried out in accordance with conventional procedures as known in the art, e.g. as illustrated in the following examples or analogously thereto. For example in step (aA) the compound of formula XIIA may conveniently be reacted with e.g. chlorosulfonic acid or with chlorosulfonic acid followed by thionyl chloride. In step (bA) the compound of formula XIA may be reacted with the compound of formula XA and e.g. triethylamine in the presence of a solvent like acetonitrile and acetone at 0°C. In step (cA) the compound of formula IXA may be reacted with the compound of formula VIIIA at room temperature in the presence of a solvent like acetonitrile, acetone or ethyl acetate, ethyl acetate being preferred. Preferably an excess of the compound of formula VIIIA may be used, e.g. a 10 % excess. In step (dA) the compound of formula VIIA may be reacted with an excess of the compound of formula VIA, e.g. a 10 % excess, in the presence of, e.g. trifluoroacetic acid and a desiccant, e.g. trimethyl orthoacetate. The reduction of step (eA) may, e.g. be accomplished via hydrogenation over 10 % palladium on carbon in the presence of a solvent, e.g. tetrahydrofuran. The hydrolysis of the ester of formula IVA [step (fA)] may be accomplished in the presence of a base like NaOH, in a solvent like ethanol, methanol, acetone or tetrahydrofuran, preferably tetrahydrofuran. In some of the above steps the reactants may be warmed prior to reaction.

Compounds of formula IIA wherein  $X^1$ ,  $R^9$  and  $R^{10}$  have the above meanings and  $X^2$  is a divalent group of formula




wherein  $R^{11}$  is  $C_1$ - $C_4$ alkyl,  $C_3$ - $C_6$ cycloalkyl, may be prepared applying known techniques, e.g. in accordance with the following reaction scheme:




wherein Hal is halogen, e.g. chlorine,  $R^{15}$  is  $C_1$ - $C_4$ alkyl, e.g. ethyl,  $y$  is 1 and  $M$  is a monovalent metal or  $y$  is 1/2 and  $M$  is a divalent metal, and  $X^1$ ,  $R^9$ ,  $R^{10}$  and  $R^{11}$  are as defined for formula IA.

Examples of a metal include an alkali metal, e.g. lithium (Li), sodium (Na) and potassium (K), an alkaline earth metal, e.g. magnesium (Mg), or manganese (Mn), iron (Fe), zinc (Zn) or silver (Ag).

Compounds of formula IIA wherein  $X^1$ ,  $R^9$  and  $R^{10}$  have the above meanings and  $X^2$  is a divalent group of formula




wherein  $R^{1A}$  and  $R^{2A}$  independently are  $C_1$ - $C_4$ alkyl or, together with the N-atom to which they are attached, represent a 5 to 7 membered heterocyclic ring, may be prepared applying known techniques, e.g. in accordance with the following reaction scheme:




wherein Hal is halogen, e.g. chlorine,  $R^{15}$  is  $C_1$ - $C_4$ alkyl, e.g. ethyl, and  $X^1$ ,  $R^{1A}$ ,  $R^{2A}$ ,  $R^9$  and  $R^{10}$  are as defined for formula IA.

Compounds of formula VIIA wherein  $X^1$ ,  $R^9$  and  $R^{10}$  have the above meanings and  $X^2$  is a divalent group of formula




wherein  $R^{11}$  is  $C_1$ - $C_4$ alkyl,  $C_3$ - $C_6$ cycloalkyl, may be prepared applying known techniques, e.g. in accordance with the following reaction scheme:



wherein Hal is halogen, e.g. Cl,  $R^{15}$  is  $C_1$ - $C_4$ alkyl, e.g. ethyl,  $y$  is 1 and M is a monovalent metal or  $y$  is 1/2 and M is a divalent metal, and  $X^1$ ,  $R^9$ ,  $R^{10}$  and  $R^{11}$  are as defined for formula IA.

Compounds of formula II may be prepared applying known techniques, e.g. in accordance with the following reaction scheme:





wherein Hal is halogen, e.g. chlorine,  $R^{15}$  is  $C_1$ - $C_4$ alkyl, e.g. ethyl, and  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ , m and n are as defined for formula I.

Each of the above reaction steps may be carried out in accordance with conventional procedures as known in the art, e.g. as illustrated in the following examples or analogously thereto. For example in step (a) the compound of formula XII may conveniently be reacted with e.g. chlorosulfonic acid or with chlorosulfonic acid followed by thionyl chloride. In step (b) the compound of formula XI is reacted with the compound of formula X and e.g. triethylamine in the presence of a solvent like acetonitrile and acetone at 0°C. In step (c) the sulfonamide of formula IX is reacted with the compound of formula VIII at room temperature in the presence of a solvent like acetonitrile, acetone or ethyl acetate, ethyl acetate being preferred. Preferably an excess of the compound of formula VIII may be used, e.g. a 10 % excess. In step (d) the compound of formula VII may be reacted with an excess of the compound of formula VI, e.g. a 10 % excess, in the presence of, e.g. trifluoroacetic acid and a desiccant, e.g. trimethyl orthoacetate. The reduction of step (e) may for example be accomplished via hydrogenation over 10 % palladium on carbon in the presence of a solvent, e.g. tetrahydrofuran. The hydrolysis of the ester of formula IV [step (f)] may be accomplished in the presence of a base like NaOH, in a solvent like ethanol, methanol, acetone or tetrahydrofuran, preferably tetrahydrofuran. In some of the above steps the reactants may be warmed prior to reaction.

Starting compounds of formula IIIA, VB, VIA, VIB, VIC, VID, VIIB, VIIIA, XA, XIB, XIC and XIIB are known or may be prepared from corresponding known compounds. Starting compounds III, VI, VIII, X and XII are known or may be prepared from corresponding known compounds.

**Example S1: Preparation of (2-(2,2-diphenyl-ethylamino)-5-[4-(4-carboxy)-piperidine-1-sulfonyl]-phenyl)-morpholin-4-yl-methanone (formula II:  $R^1 + R^2 + N =$  morpholin-4-yl,  $R^3 + R^4 =$  ethylene, m = 2, n = zero)**

(a) A 2 liter flask is charged with isatoic anhydride (180.3 g) and chlorosulfonic acid (367 ml, 643.9 g). The mixture is stirred at ambient temperature for 21 h. Thionyl chloride (80.6 ml, 131.5 g) is added over 2 h and the mixture is stirred at ambient temperature for 16 h. The reaction is worked up by slowly pouring the reaction mixture over ice (4.5 kg) with stirring. The resulting suspension is filtered and the filtercake is washed with water (2 x 500 ml). The solid is dried (40°C, house vacuum, 48 h) to give compound 2.

(b) A 5 liter flask is charged with 2 (270.2 g) and acetone (2.0 l). The suspension is cooled in an ice/methanol bath and a solution of ethyl isonipecotate (165.7 g) and TEA (156.8 g) in acetone (700 ml) is added over 1.43 h. After the addition is complete, the cooling bath is removed and the mixture is stirred for 2 h. The reaction is worked up by removing volatiles via rotary evaporation (35°C, house vacuum). The solid is triturated with 0.5 N HCl (1763 ml). The suspension is filtered and the filtercake is washed with water (1.0 l). The solid is dried (40°C, house vacuum, 3 days) to give compound 4.

(c) A 12 liter flask is charged with 4 (342.4 g) and EtOAc (3.4 l). A solution of morpholine (85.80 g) in EtOAc (340 ml) is added at ambient temperature over 1.5 h. The mixture is stirred for 30 min. The reaction is worked up by adding charcoal (35.2 g) and filtering through Celite. The solids are washed with EtOAc and the filtrate is reduced to ~2 l by rotary evaporation. Heptane (1.7 l) is added at ambient temperature over 2 h and the resulting suspension is stirred overnight. The suspension is filtered, washed with mother liquor, and dried overnight (40°C, house vacuum) to give 6.

(d) A 12 liter flask is charged with compound 6 (324.7 g) and EtOAc (4.4 l). The mixture is heated until all of the solids dissolved (~35°C). 2,2-diphenyl ethanal (164.7 g), trimethyl orthoacetate (100.8 g), and TFA (4.35 g) are added and the mixture is stirred at ambient temperature for 3 days. The reaction is worked up by removing EtOAc via rotary evaporator. The residue is triturated with TBME (3.2 l). The resulting suspension is filtered, the filtercake is washed with TBME (320 ml) and dried (40°C, house vacuum, N<sub>2</sub> purge) to give compound 8.

(e) A 2.5 liter Parr bottle is charged with compound 8 (118.8 g) and THF (1.2 l). The mixture is heated with stirring until all of the solids are dissolved (~55°C). Palladium on carbon (10 %, anhydrous, 10.47 g) is added and the mixture is shaken under a hydrogen atmosphere (50 psi) at ambient temperature for 24 h. The reaction is worked up by filtering the mixture through Celite. THF is removed by rotary evaporator. The residue is triturated with TBME (1.1 l). The resulting suspension is filtered, the filtercake is washed with TBME (110 ml) and dried (40°C, house vacuum, N<sub>2</sub> purge) to give compound 9.

(f) A 12 liter flask is charged with 9 (326.8 g), THF (3.3 l), and 1.0 N NaOH (540 ml). The biphasic solution is stirred at ambient temperature for 24 h. The reaction is worked up by removing THF via rotary evaporator. Water (1.0 l) is added to the remaining aqueous portion and 1.0 N HCl (600 ml) is added with stirring at ambient temperature over 2 h. The

resulting suspension is filtered, the filtercake is washed with water (1 l) and dried (40°C, house vacuum, N<sub>2</sub> purge) to give the title compound.

Compounds of formula II, IV, V, VII and IX are new and also an embodiment of the present invention.

The following examples for compounds of formula IIA wherein R<sup>3A</sup> and R<sup>4A</sup> together are ethylene and m is 2 are prepared analogously to Example S1:

Example	-NR <sup>1A</sup> R <sup>2A</sup>	n
II.3	3,6-dihydro-2H-pyridin-1-yl	0
II.4	piperidin-1-yl	0
II.6	thiomorpholin-4-yl	0
II.8	-N(CH <sub>3</sub> )CH <sub>2</sub> CH <sub>3</sub>	0
II.13	2,5-dihydropyrrol-1-yl	0
II.14	3,6-dihydro-2H-pyridin-1-yl	1
II.1.7	4-difluoropiperidin-1-yl	0

The following examples for compounds of formula II wherein R<sup>1</sup> and R<sup>2</sup> together with the N-atom to which they are attached are morpholinyl, and R<sup>4</sup> is H are prepared analogously to Example S1:

Example	R <sup>3</sup>	m	n	Example	R <sup>3</sup>	m	n
II.23	-CH <sub>3</sub>	1	1	II.28	benzyl	1	1
II.25	benzyl	1	0	II.29	-H	2	1
II.26	cyclohexyl	1	0	II.30	-CH <sub>3</sub>	3	1
II.27	-CH <sub>3</sub>	1	0				

The compounds of the invention and their pharmaceutically acceptable acid addition salts (hereinafter: Pharmaceutical Compounds) have pharmacological activity and are useful as pharmaceuticals. In particular Pharmaceutical Compounds exhibit bradykinin antagonist activity. In particular Pharmaceutical Compounds, e.g. compounds of Example 1 and 2, are active at the human B<sub>1</sub> bradykinin receptor.

Bradykinin receptor interaction of the Pharmaceutical Compounds is demonstrated by their ability to displace bradykinin at human bradykinin receptor sites, e.g. as demonstrated in accordance with the following test method.

**Test I:      Bradykinin receptor binding assay**

**Cloning of the human bradykinin B1 receptor cDNA:** The human bradykinin B1 receptor is cloned from WI38 human foetal lung cell fibroblast cells by expression cloning in *Xenopus laevis* oocytes, which do not express bradykinin B1 receptors normally. A cDNA library is prepared in bacteriophage lambda ZAP express and grown in pools of approximately 10,000 clones per pool. Bacteriophage DNA is prepared from these pools and copy RNA is synthesised with T3 RNA polymerase and after phenol extraction and precipitation, the RNA is injected into *Xenopus* oocytes and allowed to be expressed for 3 days. The oocytes are then assayed electrophysiologically using two electrode voltage clamp, for a response in an endogenous chloride channel that can be activated by endogenous heterotrimeric GTP binding proteins of the Gq/G11 type that can couple to bradykinin receptors. A positive clone is isolated from a positive pool by several stages of splitting the pool into smaller pools and assaying, until a single clone is isolated. This cDNA is sequenced and subcloned into pcDNA3 (Clontech) and used to generate a cell-line which expresses the human bradykinin B1 receptor.

**Making the HEK cells:** The human bradykinin B1 receptor cDNA is subcloned into the Kpn1 and Not1 sites of pcDNA3 (HB1-pcDNA3), is grown up and transfected into human embryonic kidney fibroblast cell line, HEK 293 using the Calcium phosphate method. Cells are grown in Minimum Essential Medium with Earle's Salts (GIBCO) supplemented with 2 mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, 1 % nonessential amino acids and 10 % myoclone foetal calf serum (GIBCO) in a humidified atmosphere with 5 % CO<sub>2</sub> at 37°C.

The 293Hek cells are split 1:2 the day prior to transfection. One 175 cm<sup>2</sup> flask with approximately 50 % confluent cells is transfected with approximately 30 µg/ml HB1-pcDNA3 DNA using the calcium phosphate precipitate method of transfection. The flask of transfected cells is split 1:3 on day 2 post transfection to prevent overgrowth. The following day the cells are split 1:5 and selection in 700 µg/ml G418 begins. The selective medium is changed every 3-4 days. When distinct G418 resistant colonies of transfected cells are seen, approximately 4 weeks after transfection, the cells are cloned by limiting dilution and assayed for binding of [<sup>3</sup>H]desArg<sup>10</sup>-kallidin. The clone with the highest binding is chosen for

further use. Care is taken not to allow the cells to overgrow and to maintain G418 in the growth medium.

These HEK 293 cells expressing the human bradykinin B<sub>1</sub> receptor are used to prepare membranes. Cells are homogenised in 50 mM Tris-HCl, 1 mM EDTA pH 7.4 at 10,000 rpm for 30 sec in a Polytron homogeniser. All subsequent operations are carried out at 4°C. The resultant suspension is centrifuged for 30 min at 28,000 x g. The pellet is washed a further two times by resuspension in Tris-HCl (50 mM, pH 7.4) and recentrifugation. The final pellet is resuspended in Tris-HCl (50 mM, pH 7.4), containing 5 % glycerol and frozen rapidly on dry ice in 500 µl aliquots and stored at -80°C.

For use in the binding assay, membranes are thawed, homogenised, and diluted with physiological binding buffer (10 mM HEPES, HBSS {137 mM NaCl, 5.4 mM KCl, 1.3 mM CaCl<sub>2</sub>, 0.4 mM KH<sub>2</sub>PO<sub>4</sub>, 0.3 mM NaHPO<sub>4</sub>, 0.5 mM MgCl<sub>2</sub>, 0.4 mM MgSO<sub>4</sub>, 5.6 mM glucose, pH 7.4} containing 1 mM 1-10 phenanthroline and 0.14 g/l bacitracin. Binding assays are performed in 1.2 ml polypropylene assay tubes (incorporated into a deep well block of 96 or individual Micronics tubes) containing a final volume of 0.5 ml. The assay composition is 425 µl membrane suspension (approximately 20 µg protein per tube) in physiological binding buffer, 50 µl [<sup>3</sup>H]desArg<sup>10</sup>-kallidin (specific activity 95 Ci/mMol; 6.0 ± 0.5 nM), 25 µl of either DMSO, or unlabelled desArg<sup>10</sup> kallidin (20 µM) or different concentrations of Pharmaceutical Compounds made up in DMSO. Specific binding to the bradykinin B<sub>1</sub> receptor is defined as the difference between that found in total bound tubes and that found in non-specific binding tubes. The reaction is initiated with the addition of membranes and incubated at 4°C for 60 min. The reaction is terminated by rapid filtration of the assay mixture through Canberra Packard Unifilter-96 GF/B filterplates (which have been pre-soaked in 0.6% polyethyleneimine for 2 to 3 h at RT). The filters are washed 4 times with 1 ml aliquots of ice cold wash buffer. Microscintillant-40 liquid scintillant is added to the filters and radioactivity bound is determined in a Canberra Packard Topcount scintillation counter. Binding parameters are derived from non-linear iterative curve fitting of three or four data sets simultaneously, using a logistic model in Microcal™ Origin.

K<sub>i</sub> values are 0.063 µM for the peptide antagonist desArg<sup>10</sup>HOE [(D-Arg-[Hyp<sup>3</sup>, Thi<sup>5</sup>, D-Tic<sup>7</sup>, Oic<sup>8</sup>]desArg<sup>9</sup> bradykinin) = (D-Arginine-[hydroxyproline<sup>3</sup>, thienylamine<sup>5</sup>, D-tetrahydroxyquinoline-3-carboxylic acid<sup>7</sup>, octahydroindole-2-carboxylic acid<sup>8</sup>]desArginine<sup>9</sup> bradykinin)] and in the range of 0.5 nM to 2 µM for Pharmaceutical Compounds.

Activity specifically as analgesic agents may be demonstrated in accordance with standard test methods, e.g. as described in the following test.

**Test II: Thermal antinociception in monkeys (warm water tail-withdrawal)**

Carrageenan at a dosage of 2 mg in 100 µl saline is injected subcutaneously into the terminal 1 to 4 cm of the tail of adult rhesus monkeys (*Macaca mulatta*) followed by administration of Pharmaceutical Compound in 100 µl vehicle (0.5 % methylcellulose in distilled water) or vehicle to the animal.

The animals are seated in restraint chairs and the lower part of the shaved tail (approximately 15 cm) immersed into warm water maintained at temperatures of 42, 46, and 50°C. Tail-withdrawal latencies are recorded manually by a computerized timer. A maximum cutoff latency (20 sec) is recorded if the subjects fail to remove their tails by this time. A single dosing procedure is used in all test sessions. Each experimental session begins with control determinations at each temperature. Subsequent tail withdrawal latencies are determined based on each experimental condition. The subjects are tested 1 to 2 times at three temperatures in a varying order, with approximately 1 to 2 min interval between tests. Experimental sessions are conducted once per week.

In this test Pharmaceutical Compounds are efficient in preventing or reversing carrageenan-induced hyperalgesia at a dosage in the range of from 0.01 µMole/kg to 1 mMole/kg.

Pharmaceutical Compounds are accordingly useful as bradykinin B<sub>1</sub> receptor antagonists, e.g. in the treatment of diseases and conditions in which B<sub>1</sub> receptor activation plays a role or is implicated. Such conditions include in particular pain, e.g. bone and joint pain (osteoarthritis), cancer pain, myofascial pain (muscular injury, fibromyalgia) and perioperative pain (general surgery, gynecologic surgery).

Pharmaceutical Compounds are particularly useful in the treatment or prevention of chronic pain, especially inflammatory, e.g. chronic inflammatory pain, inflammatory diseases for example inflammatory airways disease, e.g. COPD, or in asthma, rhinitis, inflammatory bowel disease, cystitis, e.g. interstitial cystitis, pancreatitis, uveitis, inflammatory skin disorders and rheumatoid arthritis.

Pharmaceutical Compounds are thus useful as bradykinin BK<sub>1</sub> receptor antagonists, e.g. for the treatment of pain of various genesis or aetiology and as anti-inflammatory and/or anti-oedemic agents for the treatment of inflammatory reactions, diseases or conditions, as well as for the treatment of allergic responses mediated by bradykinin. Having regard to their analgesic/anti-inflammatory profile they are useful for the treatment of inflammatory pain, for the treatment of hyperalgesia and, in particular, for the treatment of severe chronic pain. They are, for example, useful for the treatment of pain, inflammation and/or oedema consequential to trauma, e.g. associated with burns, sprains, fracture or the like, subsequent to surgical intervention, e.g. as post-operative analgesics, as well as for the treatment of inflammatory pain of diverse genesis, e.g. for the treatment of osteo and rheumatoid arthritis and rheumatic disease, teno-synovitis and gout. They are further suitable as analgesics for the treatment of pain associated with, e.g., angina, menstruation or cancer. As anti-inflammatory/anti-oedema agents, they are further useful, e.g., for the treatment of inflammatory skin disorders, for example psoriasis and eczema.

As bradykinin BK<sub>1</sub> receptor antagonists Pharmaceutical Compounds are also useful as smooth muscle relaxants, e.g. for the treatment of spasm of the gastro-intestinal tract or uterus, e.g. in the therapy of Crohn's disease, ulcerative colitis or pancreatitis.

Pharmaceutical Compounds are in particular useful as agents for the therapy of airways hyperreactivity and for the treatment of inflammatory events associated with airways disease, in particular asthma. In addition, Pharmaceutical Compounds may, for example, be used for the control, restriction or reversal of airways hyperreactivity in asthma.

Inflammatory or obstructive airways diseases to which the present invention is applicable include asthma of whatever type or genesis including both intrinsic and, especially, extrinsic asthma. Thus, Pharmaceutical Compounds are useful for the treatment of allergic asthma, whether atopic (i.e. IgE-mediated) or non-atopic, as well as, for example, exercise induced asthma, occupational asthma, asthma induced following bacterial infection, other non-allergic asthmas and "wheezy-infant syndrome".

Efficacy in the treatment of asthma will be evidenced by reduced frequency or severity of symptomatic attack, e.g. of acute asthmatic or bronchoconstrictor attack and by reduced requirement for other, symptomatic therapy, for example anti-inflammatory (e.g. corticosteroid) or bronchodilator (e.g.  $\beta_2$  adrenergic) therapy.

Inflammatory or obstructive airways diseases to which the present invention is applicable further include pneumoconiosis (an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by repeated inhalation of dusts) of whatever type or genesis, including, for example, aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis and, in particular, byssinosis.

Further inflammatory or obstructive airways diseases and conditions for which Pharmaceutical Compounds may be used include adult respiratory distress syndrome (ARDS), chronic obstructive pulmonary or airways disease (COPD or COAD), and bronchitis. Pharmaceutical Compounds may also be used for the treatment of allergic and vasomotor rhinitis.

In addition to the foregoing Pharmaceutical Compounds are also indicated for use in the therapy of septic shock, e.g. as anti-hypovolaemic and/or anti-hypotensive agents, in the treatment of inflammatory bowel disease cerebral oedema, headache, migraine and inflammatory skin disease such as eczema and psoriasis, and inflammatory disorders of the gut, e.g. irritable bowel syndrome, Crohn's disease, ulcerative colitis, cystitis, e.g. interstitial cystitis, nephritis, uveitis.

For the above indications the appropriate dosage of Pharmaceutical Compounds will, of course, vary depending upon, for example, the host, the mode of administration and the nature and severity of the condition being treated as well as the relative potency of the particular Pharmaceutical Compound employed. For example, the amount of active agent required may be determined on the basis of known in vitro and in vivo techniques, determining how long a particular active agent concentration in the blood plasma remains at an acceptable level for a therapeutic effect. In general, satisfactory results in animals are indicated to be obtained at daily dosages of from about 0.01 to about 20.0 mg/kg p.o. In humans, an indicated daily dosage is in the range of from about 0.7 to about 1400 mg/day p.o., e.g. from about 50 to 200 mg (70 kg man), conveniently administered once or in divided doses up to 4 x per day or in sustained release form. Oral dosage forms accordingly suitably comprise from about 1.75 or 2.0 to about 700 or 1400 mg Pharmaceutical Compound admixed with an appropriate pharmaceutically acceptable diluent or carrier therefor.



Pharmaceutical Compounds may alternatively be administered e.g. topically in the form of a cream, gel or the like for example for the treatment of conditions of the skin as hereinbefore described or by inhalation, e.g. in dry powder form, for example for the treatment of asthma.

Examples for compositions comprising Pharmaceutical Compound include, e.g. a solid dispersion, an aqueous solution, e.g. containing a solubilising agent, e.g. cyclodextrin, a microemulsion and a suspension of, e.g. a micronized hydrochloride salt of a compound of formula IA in, e.g. aqueous methyl cellulose in the range of from 0.1 to 1 %, e.g. 0.5 %. The composition may be buffered to, e.g. a pH in the range of from 3.5 to 9.5, e.g. to pH 4.5, by a suitable buffer, e.g. malic acid.

Pharmaceutical Compounds are also useful as research chemicals.

In accordance with the foregoing the present invention also provides:

(1) A pharmaceutical compound for use as a bradykinin BK<sub>1</sub> receptor antagonist, for example for use in any of the particular indications hereinbefore set forth;

(2) A pharmaceutical composition comprising a pharmaceutical compound as under (1) as active ingredient together with a pharmaceutically acceptable diluent or carrier therefor;

(2') A pharmaceutical composition for the treatment or prevention of a disease or condition in which bradykinin B<sub>1</sub> receptor activation plays a role or is implicated comprising a compound of formula IA and a carrier.

(3) A method for the treatment of any of particular indication hereinbefore set forth in a subject in need thereof which comprises administering an effective amount of a pharmaceutical compound as under (1);

(3') A method for treating or preventing a disease or condition in which bradykinin B<sub>1</sub> receptor activation plays a role or is implicated comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of formula IA.


(4) Use of a compound of formula IA for the manufacture of a medicament for the treatment or prevention of a disease or condition in which bradykinin B<sub>1</sub> receptor activation plays a role or is implicated;

(5) A process for the preparation of a compound as under (1).

The preferred Pharmaceutical Compounds for use in accordance with the invention are those of Examples 1 and 2.

## Claims

## 1. A compound of formula IA



wherein

$\text{R}^{5\text{A}}$  is  $-\text{X}^{\text{A}}-\text{R}^{6\text{A}}$  or  $-\text{N}(\text{R}^{7\text{A}})\text{R}^{8\text{A}}$ , wherein

$\text{X}^{\text{A}}$  is piperidinylene or piperazinylene,

$\text{R}^{6\text{A}}$  is H, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>3</sub>-C<sub>4</sub>alkenyl, C<sub>3</sub>-C<sub>4</sub>alkinyl, C<sub>1</sub>-C<sub>4</sub>(alkoxyalkyl), C<sub>1</sub>-C<sub>4</sub>(carboxyalkyl), a C<sub>5</sub>-C<sub>7</sub>heterocyclic group or phenyl-C<sub>1</sub>-C<sub>4</sub>alkyl;

$\text{R}^{7\text{A}}$  is amino-C<sub>2</sub>-C<sub>4</sub>alkyl or mono- or di-(C<sub>1</sub>-C<sub>5</sub>alkyl)amino-C<sub>2</sub>-C<sub>5</sub>alkyl, and

$\text{R}^{8\text{A}}$  is H, C<sub>1</sub>-C<sub>4</sub>alkyl or has the meanings as given for  $\text{R}^{7\text{A}}$ ;

$\text{X}^1$  is a divalent group of formula IA'  $-(\text{CH}_2)_n-\text{X}^3-\text{R}^{4\text{A}}-(\text{CH}_2)_m-\text{X}^4-\text{N}(\text{R}^{3\text{A}})-$  wherein

$n$  is zero or 1;

$\text{X}^3$  is CH or N;

(a)  $\text{X}^4$  is a direct bond,  $\text{R}^{3\text{A}}$  and  $\text{R}^{4\text{A}}$  together are ethylene and  $m$  is 2; or

(b)  $\text{X}^4$  is a direct bond,  $\text{R}^{3\text{A}}$  is H, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>3</sub>-C<sub>6</sub>cycloalkyl, C<sub>3</sub>-C<sub>6</sub>alkenyl, C<sub>3</sub>-C<sub>6</sub>alkinyl, C<sub>7</sub>-C<sub>10</sub>aralkyl or C<sub>6</sub>-C<sub>9</sub>heteroaralkyl,  $\text{R}^{4\text{A}}$  is H and  $m$  is 1 or 2 or 3; or

(c)  $\text{X}^4$  is  $-\text{CH}(\text{R}^{12})-$ ,  $\text{R}^{3\text{A}}$  is H and  $\text{R}^{4\text{A}}$  and  $\text{R}^{12}$  together are propylene and  $m$  is 1, or ethylene and  $m$  is 2;



$\text{X}^3$  is CH or N; and

$\text{R}^{11}$  is C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>3</sub>-C<sub>6</sub>cycloalkyl or  $-\text{NR}^{1\text{A}}\text{R}^{2\text{A}}$ , wherein


$\text{R}^{1\text{A}}$  and  $\text{R}^{2\text{A}}$  independently are C<sub>1</sub>-C<sub>4</sub>alkyl or, together with the N-atom to which they are attached, represent a 5 to 7 membered heterocyclic ring; and

$\text{R}^9$  and  $\text{R}^{10}$  independently are a phenyl or pyridine ring;

and salts thereof.

2. A 2-(2,2-diphenylethylamino)-5-(4-aminocarbonyl-piperidine-1-sulfonyl)-benzoic acid amide or -5-(aminocarbonyl-C<sub>2</sub>-C<sub>4</sub>alkyleneaminosulfonyl)-benzoic acid amide, or salt thereof.

3. A compound of formula I



wherein


R<sup>1</sup> and R<sup>2</sup> independently are C<sub>1</sub>-C<sub>4</sub>alkyl or, together with the N-atom to which they are attached, represent a 5 to 7 membered heterocyclic ring;

(a) R<sup>3</sup> and R<sup>4</sup> together are ethylene and m is 2; or

(b) R<sup>3</sup> is H, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>5</sub>-C<sub>7</sub>cycloalkyl or phenyl-C<sub>1</sub>-C<sub>4</sub>alkyl, R<sup>4</sup> is H and m is 1 or 2 or 3;

n is zero or 1; and

R<sup>5</sup> is -X-R<sup>6</sup> or -N(R<sup>7</sup>)R<sup>8</sup>, wherein



R<sup>6</sup> is C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>3</sub>-C<sub>4</sub>alkenyl, C<sub>3</sub>-C<sub>4</sub>alkinyl, C<sub>1</sub>-C<sub>4</sub>(alkoxyalkyl), C<sub>1</sub>-C<sub>4</sub>(carboxyalkyl), a C<sub>5</sub>-C<sub>7</sub>heterocyclic group or phenyl-C<sub>1</sub>-C<sub>4</sub>alkyl;


R<sup>7</sup> is amino-C<sub>2</sub>-C<sub>4</sub>alkyl or mono- or di-(C<sub>1</sub>-C<sub>5</sub>alkyl)amino-C<sub>2</sub>-C<sub>5</sub>alkyl, and

R<sup>8</sup> is H, C<sub>1</sub>-C<sub>4</sub>alkyl or has the meanings as given for R<sup>7</sup>;

and salts thereof.


4. A compound according to claim 1 which is (2-(2,2-diphenyl-ethylamino)-5-[4-(4-isopropyl-piperazine-1-carbonyl)-piperidine-1-sulfonyl]-phenyl)-morpholin-4-yl-methanone, or {2-(2,2-diphenyl-ethylamino)-5-[4-(4-methyl-piperazine-1-carbonyl)-piperidine-1-sulfonyl]-phenyl}-morpholin-4-yl-methanone.

5. A process for the production of a compound of formula IA according to claim 1 which process comprises reacting a compound of formula IIA




wherein  $X^1$ ,  $X^2$ ,  $R^9$  and  $R^{10}$  have the meanings according to claim 1,  
with an amine and recovering the obtained compound in free or in salt form.

6. A process for the production of a compound of formula I according to claim 3, which process comprises reacting a compound of formula II



wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $m$  and  $n$  have the meanings according to claim 3, with an amine and recovering the obtained compound in free or in salt form.

7. A process for the production of a compound of formula II according to claim 6, which process comprises the steps as outlined in the following scheme:



wherein Hal is halogen, R<sup>15</sup> is C<sub>1</sub>-C<sub>4</sub>alkyl, and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, m and n are as defined in claim 3.

8. A compound according to claim 1 for use in the treatment of the human or animal body.

9. Use of a compound according to claim 1 for the manufacture of a medicament for the treatment or prevention of a disease or condition in which bradykinin B<sub>1</sub> receptor activation plays a role or is implicated.

10. A method for treating or preventing a disease or condition in which bradykinin B<sub>1</sub> receptor activation plays a role or is implicated comprising administering to a mammal in need thereof a therapeutically effective amount of a compound according to claim 1.

11. A pharmaceutical composition for the treatment or prevention of a diseases or condition in which bradykinin B<sub>1</sub> receptor activation plays a role or is implicated comprising a compound according to claim 1 and a carrier.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 December 2000 (14.12.2000)

PCT

(10) International Publication Number  
**WO 00/75107 A3**

(51) International Patent Classification<sup>7</sup>: C07C 311/44,  
C07D 211/62, 211/34, 401/12, 295/18, A61K 31/63, A61P  
29/00

Perry Court, Clerk Maxwell Road, Cambridge CB3 0RS  
(GB). RITCHIE, Timothy, John [GB/GB]; 56 Burrard  
Road, London NW6 1DD (GB). WAYKOLE, Liladhar  
[US/US]; 11 Putters Road, Succasunna, NJ 07876 (US).

(21) International Application Number: PCT/EP00/05059

(22) International Filing Date: 2 June 2000 (02.06.2000)

(74) Agent: BECKER, Konrad; Novartis AG, Corporate In-  
tellectual Property, Patent & Trademark Dept., CH-4002  
Basel (CH).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9913079.1 4 June 1999 (04.06.1999) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,  
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,  
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,  
TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except AT, US*): NO-  
VARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058  
Basel (CH).

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for AT only*): NOVARTIS-ERFINDUNGEN  
VERWALTUNGSGESELLSCHAFT MBH [AT/AT];  
Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

Published:


— with international search report

(75) Inventors/Applicants (*for US only*): BRAIN, Christo-  
pher, Thomas [GB/GB]; 54 Cardinal's Gate, Wer-  
rington, Peterborough, Cambridgeshire PE7 5A (GB).  
CANTRELL, William [US/US]; 307 Laurel Ridge Drive,  
San Antonio, TX 78253 (US). CULSHAW, Andrew,  
James [GB/GB]; 10 Bracewell Avenue, Greenford, Mid-  
dlesex UB6 7QU (GB). DZIADULEWICZ, Edward,  
Karol [GB/GB]; 83 Wellsway, Bear Flat, Bath, Somerset  
BA2 4RU (GB). HART, Terance, William [GB/GB]; 12

(88) Date of publication of the international search report:  
7 September 2001

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: BRADYKININ RECEPTOR ANTAGONISTS



(57) Abstract: Novel sulfonyl amine derivatives, of formula  
(IA) processes for their production, their use as pharmaceuticals  
and pharmaceutical compositions comprising them.

WO 00/75107 A3

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/EP 00/05059

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C311/44 C07D211/62 C07D211/34 C07D401/12 C07D295/18  
A61K31/63 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C07C A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 25315 A (SANOFI SA ; FERRARI BERNARD (FR); GOUGAT JEAN (FR); MUNEUX CLAUDE) 17 July 1997 (1997-07-17) abstract -----	1-11

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "A" document member of the same patent family

Date of the actual completion of the international search

8 March 2001

Date of mailing of the international search report

03. 08. 2001

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 851 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

De Jong, B



# INTERNATIONAL SEARCH REPORT

international application No.  
PCT/EP 00/05059

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claim 10 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/05059

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9725315 A	17-07-1997	FR 2743562 A	18-07-1997
		AU 1383297 A	01-08-1997
		BR 9707120 A	20-07-1999
		CA 2241788 A	17-07-1997
		EP 0877737 A	18-11-1998
		JP 2000504315 T	11-04-2000
		NO 983190 A	10-07-1998
		US 6015812 A	18-01-2000
		US 6100278 A	08-08-2000